BRE-AD01 / Brexogen  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BRE-AD01 / Brexogen
NCT06055361: A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Recruiting
1
45
US
BxC-I17e, Placebo
Brexogen Inc.
Atopic Dermatitis
12/25
12/25
NCT06055374: A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Withdrawn
1
18
NA
BxC-I17e, Placebo
Brexogen Inc.
Atopic Dermatitis
04/25
08/25

Download Options